Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques

TerminatedOBSERVATIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Renal Cell Carcinoma
Trial Locations (12)

15706

Complejo Hospitalario Univ de Santiago de Compostela, Santiago de Compostela

20080

Hospital de Donostia, San Sebastián

24071

Complejo Hospitalario de León, León

27003

Hospital Univ Lucus Augusti, Lugo

31008

Hospital de Navarra, Pamplona

32005

Complejo Hospitalario de Ourense, Ourense

33011

Hospital Universitario central de Asturias, Oviedo

36204

Complejo Hospitalario Univ de Vigo, Vigo

46009

Instituto Valenciano de Oncologia, Valencia

46026

Hospital Universitario La Fe, Valencia

50009

Hospital Miguel Servet, Zaragoza

08208

Consorcio Hospitalario Parc Tauli, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Spanish Oncology Genito-Urinary Group

OTHER

NCT02747173 - Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques | Biotech Hunter | Biotech Hunter